IL6 and COVID-19: This family includes the monoclonal antibodies Tocilizumab [44] and Sarilumab [45], which both inhibit Interleukin-6 (IL-6) signaling; Anakinra [46], which interferes instead with IL-1 signaling; and the Janus Kinase (JAK) inhibitor Baricitinib [47], alone or in conjunction with Remdesivir [48], with the latest representing maybe the most successful example of drug repurposing against COVID-19 being the first approved drug against this illness [49].